2540 related articles for article (PubMed ID: 26544944)
1. The Molecular Taxonomy of Primary Prostate Cancer.
Cancer Genome Atlas Research Network
Cell; 2015 Nov; 163(4):1011-25. PubMed ID: 26544944
[TBL] [Abstract][Full Text] [Related]
2. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
[TBL] [Abstract][Full Text] [Related]
3. NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer.
Tang L; Zhang L; Liu L; Dong L; Dong Y; Zhu W; Wang H
FEBS Open Bio; 2020 Dec; 10(12):2678-2686. PubMed ID: 33058520
[TBL] [Abstract][Full Text] [Related]
4. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
6. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
[TBL] [Abstract][Full Text] [Related]
7. Pioneer of prostate cancer: past, present and the future of FOXA1.
Teng M; Zhou S; Cai C; Lupien M; He HH
Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
[TBL] [Abstract][Full Text] [Related]
8. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
9. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
Mao N; Gao D; Hu W; Hieronymus H; Wang S; Lee YS; Lee C; Choi D; Gopalan A; Chen Y; Carver BS
Mol Cancer Ther; 2019 Sep; 18(9):1577-1586. PubMed ID: 31296553
[TBL] [Abstract][Full Text] [Related]
11. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer.
Zhao Y; Hu X; Yu H; Liu X; Sun H; Shao C
Cell Mol Life Sci; 2022 Jul; 79(8):436. PubMed ID: 35864178
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells.
Yang L; Wang L; Lin HK; Kan PY; Xie S; Tsai MY; Wang PH; Chen YT; Chang C
Biochem Biophys Res Commun; 2003 Jun; 305(3):462-9. PubMed ID: 12763015
[TBL] [Abstract][Full Text] [Related]
14. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
15. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.
Cai C; Hsieh CL; Omwancha J; Zheng Z; Chen SY; Baert JL; Shemshedini L
Mol Endocrinol; 2007 Aug; 21(8):1835-46. PubMed ID: 17505060
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.
Nitschke K; Erben P; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Wahby S; Nuhn P; Boutros M; Michel MS; von Hardenberg J; Worst TS
World J Urol; 2020 Mar; 38(3):637-645. PubMed ID: 30701334
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer.
Avila DM; Zoppi S; McPhaul MJ
J Steroid Biochem Mol Biol; 2001; 76(1-5):135-42. PubMed ID: 11384871
[TBL] [Abstract][Full Text] [Related]
18. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
20. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]